HOME >> BIOLOGY >> NEWS
Promising multi-strain HIV vaccine candidate emerges

BALTIMORE, Md.--AIDS researchers have developed a candidate vaccine strategy that, for the first time, demonstrates an ability to elicit antibodies that block the infection of multiple HIV virus strains -- an elusive scientific goal that has been pursued for a decade.

The candidate vaccine - still early in developmental stages at the Institute of Human Virology (IHV) -- is described in a report to appear during the week of Aug. 19-23 in the U.S. Proceedings in the National Academy of Sciences (PNAS). It is authored by Drs. Timothy Fouts, Anthony Devico, and colleagues at the IHV, a center of the University of Maryland Biotechnology Institute and affiliated with the University of Maryland Medical Center, and Dr. Ranajit Pal and colleagues at Advanced BioScience Laboratories, Inc. (ABL) in Kensington, Md.

One of the major challenges in developing an effective AIDS vaccine has long been the fact that the virus that causes AIDS, much like the influenza virus, exists as multiple strains that present many different faces to the immune system, say the authors. The surface of the AIDS virus, HIV, is coated with a protein called gp120 that has chemical features that vary from strain to strain. It has been difficult for researchers to find a single vaccine component that is able to generate antibodies that recognize the many forms of gp120 that exist in nature.

The IHV/ABL research team approached the problem by recognizing that all gp120 molecules have a shared characteristic that allows all HIV strains to bind a molecule on human target cells called CD4. Importantly, once gp120 forms a complex with CD4, it undergoes structural and chemical changes that reveal features shared by all HIV strains.

Taking advantage of this knowledge, the team produced artificial gp120-CD4 complexes that were chemically treated in order to glue or "crosslink" them together. The complexes were then used to generate antibodies in small animals and monkeys.'"/>

Contact: Gwen Fariss Newman
newmang@umbi.umd.edu
410-706-4616
University of Maryland Biotechnology Institute
19-Aug-2002


Page: 1 2 3

Related biology news :

1. Promising hospital anti-infection strategy probably wont work, study shows
2. Promising research: From employment issues to virology
3. Promising new tool shows how dividing cells finish what they start
4. Promising biomarker for melanoma is identified
5. Promising new therapies for deadly form of leukemia
6. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
7. SFU Spin-Off Company To Research Promising Antibacterial Agents
8. SFU Molecular Biologist Pursues Promising New Way To Fight Disease
9. UNC-CH Researchers Develop Promising Heart Research Tool
10. Duke Researchers Call Gene Therapy A Promising Strategy For Sickle Cell Anemia
11. Promising Fatty Acid Research Leads To MS Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Promising multi strain HIV vaccine candidate emerges

(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... German . Why ... order to reproduce? And why are there two sexes anyway? ... issue of the research journal Molecular Human Reproduction ... from Bielefeld University Bielefeld has compiled this special issue on ... female to copulate with several males in quick succession – ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: